IntegraGen SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0010908723
EUR
0.14
0 (-2.44%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About IntegraGen SA stock-summary
stock-summary
IntegraGen SA
Pharmaceuticals & Biotechnology
Integragen SA is a France-based company active in the healthcare sector. It researches and develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes and obesity. It uses an evaluation model with several autism-related genes using a combination of several common polymorphisms (Single-Nucleotide Polymorphism or SNP or common variant). It also develops molecular biomarker validation programs for Hepatocellular Carcinoma and anti-epidermal growth factor receptor (anti-EGFR) resistance markers. The Company also provides genomics services to practitioners and researchers, such as DNA extraction, marker selection and tagging and bioinformatical analysis of sequence data in such fields as pharmacogenetics, cytogenetics, epigenetics, search for mutations and SNP discovery, among others. As of December 31, 2011, the Company operated through a wholly owned subsidiary, IntegraGen Inc.
Company Coordinates stock-summary
Company Details
Genopole Campus 1, Genavenir 8 5 rue Henri Desbrueres EVRY None : 91000
stock-summary
Tel: 33 1 60910900
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Bernard Courtieu
Chairman of the Board, Chief Executive Officer
Dr. Benoit Adelus
Director
Mr. Philippe Boucheron
Director, representing CDC Entreprises
Cyril Harfouche
Director
Dr. Louis Nisbet
Director, representing Kurma Life Sciences Partners
Mme. Chantal Parpex
Director, representing CDC Innovation
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 1 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.30

stock-summary
Return on Equity

-154.73%

stock-summary
Price to Book

1.11